All In Biotech

Drug Trial Radar · NCT01011660

Effects of Angiotensin II Receptor Blocker Compared With Diuretics in High-risk Hypertensive Patients

Phase 4 Study of Effects of ARB Compared With Diuretics in Hypertension Patients With High Cardiovascular Risks

Last checked: Nov 19, 2026Latest source record: Aug 13, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 13,542 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

13,542

Planned (sponsor's estimate)

Start

Oct 2007

Primary completion

Aug 2012

Study completion Dec 2012

Sponsor

Lead sponsor
Chinese Academy of Medical Sciences, Fuwai HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 11, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Factorial
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 50 years, up to 79 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of the study is to investigate the optimized treatment strategy of hypertension, so as to make more patients to reach the blood pressure goals and to reduce cardio-cerebrovascular events. Objective and Methods: Patients are eligible for inclusion in the study if they are essential hypertension, 50-79 years of age with at least one cardiovascular risk factor and sign the informed consent forms. This project is a multi-centre, prospective randomized,,openlabel blind-endpoint evaluation controlled (PROBE) trial. 12000 patients will be randomly assigned to either of low-dose Amlodipine+Telmisartan group or Amlodipine+ diuretics group. Among those patients with serum cholesterol between 4.0-6.1mmol/L, they will be also randomized into small dose of statin-based regimen or standard management regimen; Patients will also randomly assigned to intensive lifestyle intervention group or standard intervention group according to the community area where the patients in.

Conditions

  • Essential Hypertension

Interventions

  • Amlodipine, Telmisartan, Amiloride Compound , SimvastatinDrug

    Amlodipine; Telmisartan; Amiloride Compound; Simvastatin

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The primary study outcomes are composite of non-fatal stroke, non-fatal myocardial infarction and cardiovascular death.Time frame: 3-4 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Wang Wen

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.